Amphastar Pharmaceuticals vs Liquidia
AMPH and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMPH and LQDA compare
Liquidia is the larger company, worth 4.1 times as much as Amphastar Pharmaceuticals ($4.9B against $1.2B).
Liquidia grew revenue faster over the last twelve months (798% versus 3.1% for Amphastar Pharmaceuticals).
Amphastar Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 13.3% compared with −15.1% at Liquidia.
Amphastar Pharmaceuticals scores higher on the StockData Score (13 against 10 for Liquidia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMPH | LQDA |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $4.9B |
| Share price | $28.60 | $55.21 |
| Change, 1 year | 9.5% | 103% |
| Change, 5 years | 39.4% | 1196% |
| Beta (5Y) | 0.57 | 0.96 |
| Employees | 163 | 216 |
| StockData Score | ||
| Total score | 13 (better) | 10 |
| Valuation score | 6 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.0× | – |
| P/S | 1.6× (better) | 7.9× |
| P/B | 1.5× | – |
| EV/EBITDA | 11.4× | – |
| P/FCF | 8.8× (better) | 17.0× |
| PEG | 2.47 | – |
| FCF yield | 11.4% (better) | 5.9% |
| Fair value | $42.53 | – |
| Margin of safety | 32.7% | – |
| Growth | ||
| Revenue growth (TTM) | 3.1% | 798% (better) |
| Revenue growth, 5Y average | 15.5% | 192% (better) |
| Net income growth (TTM) | −11.3% | – |
| EPS growth (TTM) | −2.7% | – |
| EPS growth, 5Y average | 132% | – |
| Profitability | ||
| Gross margin | 46.8% | – |
| Operating margin | 18.7% (better) | −15.6% |
| Net margin | 13.3% (better) | −15.1% |
| FCF margin | 18.6% | 46.8% (better) |
| Return on equity | 12.4% | – |
| Return on invested capital | 9.3% | – |
| Financial health | ||
| Debt / equity | 0.75 | – |
| Net debt / EBITDA | 2.74 | – |
| Interest coverage | 5.3× | – |
| Current ratio | 3.32 (better) | 1.02 |
| Altman Z-score | 2.42 | 3.14 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 7.9% | – |
| Shareholder yield | 7.9% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 66.6% | 81.1% |
| Held by insiders | 38.7% | 19.5% |
| Insider net buying, 12 months | −$1.9M (better) | −$227M |
| Short interest, % of float | 16.3% | 24.3% |
Go deeper
- AMPH stock overview
- AMPH income statement
- AMPH valuation and score
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.